Effects of the long‐term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study

No abstract is available for this paper.

• Publication year

  2012

• Venue

  European Journal of Heart Failure

• Publication date

  2012-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/eurjhf/hfr161PMID 22147202
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Nebivolol

  2012cited by this paper
• Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial

  2011cited by this paper
• Quality of life is impaired similarly in heart failure patients with preserved and reduced ejection fraction

  2011cited by this paper
• Effects of Nebivolol on Vascular Endothelial and Myocardial Function in Diabetes Mellitus

  2011cited by this paper
• Anaemia among patients with heart failure and preserved or reduced ejection fraction: results from the SENIORS study

  2011cited by this paper
• Predictors of clinical outcomes in elderly patients with heart failure

  2011cited by this paper
• Chapter 46 – Antagonism of the Sympathetic Nervous System in Heart Failure

  2011cited by this paper
• Effect of the long-term administration of nebivolol on clinical symptoms, exercise capacity and left ventricular function in patients with heart failure and preserved left ventricular ejection fraction: background, aims and design of the ELANDD study

  2010cited by this paper
• Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure).

  2009cited by this paper
• Nebivolol: the somewhat-different beta-adrenergic receptor blocker.

  2009cited by this paper
• beta(3)-Adrenoceptor stimulation on top of beta(1)-adrenoceptor blockade "Stop or Encore?".

  2009cited by this paper
• Distinct myocardial effects of beta-blocker therapy in heart failure with normal and reduced left ventricular ejection fraction.

  2009influential reference
• Impaired Heart Rate Recovery and Chronotropic Incompetence in Patients With Heart Failure With Preserved Ejection Fraction

  2009cited by this paper
• Chronotropic incompetence, beta‐blockers, and functional capacity in advanced congestive heart failure: Time to pace?

  2008cited by this paper
• Nitric oxide: the missing lusitrope in failing myocardium.

  2008cited by this paper
• ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008 ‡

  2008cited by this paper
• Irbesartan in patients with heart failure and preserved ejection fraction.

  2008cited by this paper
• Prognosis of heart failure with preserved ejection fraction: a 5 year prospective population-based study.

  2008cited by this paper
• How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology.

  2007cited by this paper
• Diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence:results from the CHARM Echocardiographic Substudy-CHARMES.

  2007cited by this paper
• Systolic and diastolic heart failure in the community.

  2006cited by this paper
• Impaired Chronotropic and Vasodilator Reserves Limit Exercise Capacity in Patients With Heart Failure and a Preserved Ejection Fraction

  2006cited by this paper
• Trends in prevalence and outcome of heart failure with preserved ejection fraction.

  2006cited by this paper
• Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS).

  2005cited by this paper
• Differences between patients with a preserved and a depressed left ventricular function: a report from the EuroHeart Failure Survey.

  2004cited by this paper
• Nitric oxide's role in the heart: control of beating or breathing?

  2004cited by this paper
• Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial.

  2003cited by this paper
• β‐Blocker treatment of patients with diastolic heart failure and arterial hypertension. A prospective, randomized, comparison of the long‐term effects of atenolol vs. nebivolol

  2003cited by this paper
• Differential Effects of β-Blockers in Patients With Heart Failure

  2000cited by this paper
• Differential effects of beta-blockers in patients with heart failure: A prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol.

  2000cited by this paper
• Perindopril for elderly people with chronic heart failure: the PEP‐CHF study

  1999cited by this paper
• How to diagnose diastolic heart failure

  1998cited by this paper
• Effects of neurohormonal antagonism on symptoms and quality-of-life in heart failure.

  1998cited by this paper
• European Study Group on Diastolic Heart Failure

  1998cited by this paper
• How to diagnose diastolic heart failure. European Study Group on Diastolic Heart Failure.

  1998cited by this paper
• Prevalence, clinical features and prognosis of diastolic heart failure: an epidemiologic perspective.

  1995cited by this paper
• Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO-dependent mechanism.

  1995cited by this paper
• Effect of antihypertensive medication on endurance exercise capacity in hypertensive sportsmen.

  1991cited by this paper
• Effects of cardioselective and nonselective beta-adrenergic blockade on the performance of highly trained runners.

  1985cited by this paper
• Acute response to submaximal and maximal exercise consequent to beta-adrenergic blockade: implications for the prescription of exercise.

  1985cited by this paper

• Revisiting Beta-blockers in Heart Failure with Preserved Ejection Fraction- A Systematic Review and Meta-Analysis.

  2026cites this paper
• Beta-Blockers in Pulmonary Arterial Hypertension: Physiology Getting in Biology's Way.

  2025cites this paper
• Nebivolol in the therapeutic landscape of heart failure: Mechanisms and clinical outcomes.

  2025cites this paper
• Uncertainties About Use of β-Blockers in Heart Failure With Preserved Ejection Fraction.

  2025cites this paper
• Unmasking Left Ventricular Diastolic Dysfunction: Pathophysiology, Diagnosis, and Treatment Strategies

  2025cites this paper
• Beta-Blockers in Heart Failure With Preserved Ejection Fraction: A Declining Role in Contemporary Management.

  2025cites this paper
• A multi-center, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of Fuzheng Yangxin Granule in treating heart failure with preserved ejection fraction (Qi-Yin deficiency and blood stasis syndrome): study protocol

  2025cites this paper
• Patients after myocardial infarction with chronic heart failure with preserved left ventricular ejection fraction: the issue of prescribing beta blockers. The results of a 2-year prospective study

  2025cites this paper
• Primary heart failure with preserved ejection fraction: The intertwined pathophysiology and treatment of some of the most relevant phenotypes.

  2025cites this paper
• Chronic Heart Failure and Coronary Artery Disease: Pharmacological Treatment and Cardiac Rehabilitation

  2025cites this paper
• Adjunctive therapy with an oral H2S donor provides additional therapeutic benefit beyond SGLT2 inhibition in cardiometabolic heart failure with preserved ejection fraction

  2024cites this paper
• Chronotropic Incompetence across Heart Failure Categories.

  2024cites this paper
• Association of Beta Blocker Use with Exercise Capacity in Participants with Heart Failure with Preserved Ejection Fraction: A Post-Hoc Analysis of the RELAX Trial.

  2024cites this paper
• Diastolic Dysfunction in Hypertension: A Comprehensive Review of Pathophysiology, Diagnosis, and Treatment.

  2024cites this paper
• The Canadian Heart Failure (CAN-HF) Registry: A Canadian Multicentre, Retrospective Study of Outpatients with Heart Failure

  2024cites this paper
• Coronary microvascular dysfunction and left heart filling pressures in patients with type 2 diabetes

  2024cites this paper
• Differences in the Effects of Beta-Blockers Depending on Heart Rate at Discharge in Patients With Heart Failure With Preserved Ejection Fraction and Atrial Fibrillation

  2024cites this paper
• "HFpEF and Sex: Understanding the Role of Sex Differences".

  2024cites this paper
• Renal denervation improves mitochondrial oxidative stress and cardiac hypertrophy through inactivating SP1/BACH1-PACS2 signaling.

  2024cites this paper
• Early Renal Denervation Attenuates Cardiac Dysfunction in Heart Failure With Preserved Ejection Fraction

  2024cites this paper
• Impact of coronary microvascular dysfunction in heart failure with preserved ejection fraction: a meta‐analysis

  2024cites this paper
• Drug Therapy for Acute and Chronic Heart Failure with Preserved Ejection Fraction with Hypertension: A State-of-the-Art Review

  2024cites this paper
• Effect of nebivolol monotherapy or combination therapy on blood pressure levels in patients with hypertension: an updated systematic review and multilevel meta-analysis of 91 randomized controlled trials

  2024cites this paper
• The sympathetic nervous system in heart failure with preserved ejection fraction

  2024cites this paper
• Role of Bisoprolol in Heart Failure Management: A Consensus Statement from India.

  2023cites this paper
• Revisiting beta-blocker therapy in heart failure with preserved ejection fraction.

  2023cites this paper
• Medications for specific phenotypes of heart failure with preserved ejection fraction classified by a machine learning-based clustering model

  2023cites this paper
• Management of Heart Failure With Preserved Ejection Fraction in Elderly Patients: Effectiveness and Safety

  2023cites this paper
• Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension

  2023cites this paper
• The controversial role of beta-blockers in heart failure with preserved ejection fraction.

  2023cites this paper
• Diastolic Cardiomyopathy Secondary to Experimentally Induced Exacerbated Emphysema.

  2023cites this paper
• The prevalence of coronary microvascular dysfunction (CMD) in heart failure with preserved ejection fraction (HFpEF): a systematic review and meta-analysis

  2023cites this paper
• Beta-blockers in chronic heart failure with preserved left ventricular ejection fraction: is deprescribing possible?

  2023cites this paper
• Effects and Optimal Dose of Exercise on Endothelial Function in Patients with Heart Failure: A Systematic Review and Meta-Analysis

  2023influential citation
• Could SGLT2 Inhibitors Improve Exercise Intolerance in Chronic Heart Failure?

  2022cites this paper
• Can Iron Play a Crucial Role in Maintaining Cardiovascular Health in the 21st Century?

  2022cites this paper
• Betablockers reduce oxygen pulse increase and performance in heart failure patients with preserved ejection fraction.

  2022cites this paper
• Progress and prospects of Sacubitril/Valsartan: Based on heart failure with preserved ejection fraction.

  2022cites this paper
• Optimal Pharmacologic Treatment of Heart Failure With Preserved and Mildly Reduced Ejection Fraction

  2022cites this paper
• Bibliometric and visual analysis of coronary microvascular dysfunction

  2022cites this paper
• Sudden Death and Ventricular Arrhythmias in Heart Failure With Preserved Ejection Fraction

  2022cites this paper
• Comorbidities in heart failure with preserved ejection fraction

  2022cites this paper
• Circulating S‐Glutathionylated cMyBP‐C as a Biomarker for Cardiac Diastolic Dysfunction

  2022cites this paper
• Heart Failure with Preserved Ejection Fraction

  2022cites this paper
• Heart failure with preserved ejection fraction update: A review of clinical trials and new therapeutic considerations

  2022cites this paper
• Erhalt von Leistungsfähigkeit und Lebensqualität bei chronischer Herzinsuffizienz

  2022cites this paper
• The Link Between Heart Rate, Exercise, and β-Blocker in HFpEF: Time to Untie the Knot.

  2021cites this paper
• Efficacy and Safety of Qishen Yiqi Dripping Pill for Heart Failure With Preserved Ejection Fraction: A Systematic Review and Meta-Analysis

  2021cites this paper
• The Impact of beta blockade on the cardio-respiratory system and symptoms during exercise

  2021cites this paper
• Heart failure with preserved ejection fraction – onset

  2021cites this paper
• Hypertension and heart failure with preserved ejection fraction: position paper by the European Society of Hypertension

  2021cites this paper
• How to Estimate the Optimal Heart Rate in Patients with Heart Failure with Preserved Ejection Fraction.

  2021cites this paper
• Advanced Heart Failure in a Special Population: Heart Failure with Preserved Ejection Fraction.

  2021cites this paper
• Atrial Fibrillation and Heart Failure with Preserved Ejection Fraction: Two Chronic Troublemakers.

  2021cites this paper
• Clinical assessment of endothelial function in heart failure with preserved ejection fraction: A meta‐analysis with meta‐regressions

  2021cites this paper
• Effect of β-Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction.

  2021cites this paper
• Rationale for the Use of Pirfenidone in Heart Failure With Preserved Ejection Fraction

  2021cites this paper
• Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.

  2021cites this paper
• Determinants and consequences of heart rate and stroke volume response to exercise in patients with heart failure and preserved ejection fraction

  2021cites this paper
• Diagnosis and treatment of heart failure with preserved left ventricular ejection fraction

  2020cites this paper
• Association between bisoprolol plasma concentration and worsening of heart failure: (CVI ARO 6).

  2020cites this paper
• [Frequency of use and Indications for Beta-Blockers in Heart Failure with Preserved Ejection Fraction].

  2020cites this paper
• Sex-specific difference in the association between arterial stiffness and subclinical left ventricular dysfunction.

  2020cites this paper
• Effect of beta-blockers on heart failure severity in patients with heart failure with preserved ejection fraction: a meta-analysis of randomized controlled trials

  2020cites this paper
• Heart failure with preserved ejection fraction diagnosis and treatment: An updated review of the evidence.

  2020cites this paper
• Improving exercise capacity and quality of life using non‐invasive heart failure treatments: evidence from clinical trials

  2020cites this paper
• Machine Learning in Cardiology—Ensuring Clinical Impact Lives Up to the Hype

  2020cites this paper
• Treatment of Heart Failure with Preserved Ejection Fraction

  2020cites this paper
• Beta‐blockers withdrawal in patients with heart failure with preserved ejection fraction and chronotropic incompetence: Effect on functional capacity rationale and study design of a prospective, randomized, controlled trial (The Preserve‐HR trial)

  2020cites this paper
• [Beta-blockers in heart failure with preserved ejection fraction: Prescribe or deprescribe?]

  2020cites this paper
• Falla Cardíaca con Fracción de Eyección Preservada: Un Problema de la Cardiología Contemporánea

  2020cites this paper
• Evaluation and management of heart failure with preserved ejection fraction

  2020cites this paper
• Role of Ivabradine in Patients with Heart Failure with Preserved Ejection Fraction

  2020cites this paper
• Narrative review: the holy grail: update on pharmacotherapy for heart failure with preserved ejection fraction

  2020cites this paper
• Six-minute walk test: prognostic value and effects of nebivolol versus placebo in elderly patients with heart failure from the SENIORS trial

  2020cites this paper
• Therapeutic approaches in heart failure with preserved ejection fraction: past, present, and future

  2020cites this paper
• Heart Failure With Preserved Ejection Fraction: A Comprehensive Review and Update of Diagnosis, Pathophysiology, Treatment, and Perioperative Implications.

  2020cites this paper
• Prognostic impact of mineralocorticoid receptor antagonist in patients with heart failure with preserved ejection fraction

  2020cites this paper
• Reappraisal on pharmacological and mechanical treatments of heart failure

  2020cites this paper
• Hypertension as a Road to Treatment of Heart Failure with Preserved Ejection Fraction

  2020cites this paper
• Impact of β-Blockers on Heart Rate and Oxygen Uptake During Exercise and Recovery in Older Patients With Heart Failure With Preserved Ejection Fraction.

  2019cites this paper
• Association of β-Blocker Use With Heart Failure Hospitalizations and Cardiovascular Disease Mortality Among Patients With Heart Failure With a Preserved Ejection Fraction

  2019cites this paper
• Human Heart Cardiomyocytes in Drug Discovery and Research: New Opportunities in Translational Sciences.

  2019cites this paper
• Chronotropic Incompetence.

  2019cites this paper
• [Heart failure with preserved left ventricular ejection fraction].

  2019cites this paper
• Heart Rate and Heart Failure With Preserved Ejection Fraction: Time to Slow β-Blocker Use?

  2019cites this paper
• Novel paradigms in the therapeutic management of heart failure with preserved ejection fraction: clinical perspectives.

  2019cites this paper
• Treatment of Heart Failure With Preserved Ejection Fraction (HFpEF): the Phenotype-Guided Approach

  2019cites this paper
• Indications for β‐Blocker Prescriptions in Heart Failure with Preserved Ejection Fraction

  2019cites this paper
• Does beta-blockade improve cardiopulmonary exercise testing variables and other related static cardiac function measures? : systemic review, meta-analysis and prospective interventional drug trial : improving cardiac function in high-risk surgical patients (ICAF-beta) : cardiopulmonary exercise test

  2019influential citation
• Features of pharmacotherapy β1- adrenoblocker with activation of endothelial nitric oxide nebivolol in patients with coronary heart disease on the background of chronic heart failure (review of literature)

  2018influential citation
• Combination Therapy of Renin Angiotensin System Inhibitors and β-Blockers in Patients with Heart Failure.

  2018cites this paper
• Exercise training in heart failure patients: effects on skeletal muscle abnormalities and sympathetic nervous activity—a literature review

  2018cites this paper
• Treatment of Heart Failure with Preserved Ejection Fraction.

  2018cites this paper
• The right ventricle in heart failure with preserved ejection fraction

  2018cites this paper
• New drugs in preclinical and early stage clinical development in the treatment of heart failure

  2018cites this paper
• CSI position statement on management of heart failure in India

  2018cites this paper
• Mechanisms, diagnosis, and treatment of heart failure with preserved ejection fraction and diastolic dysfunction

  2018cites this paper
• Heart failure with mid-range ejection fraction and with preserved ejection fraction

  2018cites this paper
• Beta-blocker use and cardiovascular event risk in patients with heart failure with preserved ejection fraction

  2018cites this paper